NAVB: Message Board for Navidea Biopharmaceuticals, Inc. - InvestorVillage

NAVB   /  Message Board

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous 2500 Messages Top of Message List
Go to Msg #  
MSG # SUBJECT TYPE AUTHOR SENTIMENT RECS DATE POSTED
24271 Re:... April 23 -25--NASH Summit NAVB headline: "YES, YES, YES..CAN TARGET/LOCALIZE/IMAGE M1" and M2 GN roundhill 0 4/23/2018 11:01:19 PM
24270 Re:... April 23 -25--NASH Summit NAVB headline: "YES, YES, YES..CAN TARGET/LOCALIZE/IMAGE M1" and M2 GN Iwinshortslose2 0 4/23/2018 6:32:34 PM
24269 Re:... April -25--NASH Summit NAVB: --MG Presentation Outline-localization in humans and animals and animal therapeutics targeting ..15 minutes, plus 15 minute Q&A (edit presenters have 30 minutes) GN moneyonomics 5 4/23/2018 6:20:42 PM
24268 Re:... April -25--NASH Summit NAVB headline: "YES....CAN TARGET/LOCALIZE/IMAGE M1" and M2 GN moneyonomics 4 4/23/2018 3:36:29 PM
24267 Stock is run by losers GN NEOP INVESTOR Strong Sell 0 4/23/2018 10:48:41 AM
24266 Reverse Split votes count - send me your shares count and decision y/n/u GN GoTrump 2 4/23/2018 9:31:41 AM
24265 Support for macrophage science: M. McGrath, MD, et al file patent application for treating and biomarker identification in certain macrophage related diseases. No claim on CD206/209, broad claim for inflammatory factors Interleukins/cytokines in TAMS... GN moneyonomics 0 4/22/2018 6:50:15 PM
24264 Re: Facts: In 5 year period from 2013 thru 2017 re-engineered Development/R&D spending for Manocept/Macrophage up by a nearly 500% increase, up from $504k to $2.98mm, while cutting total Dev/R&D by $12.3mm or 78% ($15.6mm to $3.3mm-before credits) GN Iwinshortslose2 0 4/22/2018 5:34:00 PM
24263 Re: Facts: In 5 year period from 2013 thru 2017 re-engineered Development/R&D spending for Manocept/Macrophage up by a nearly 500% increase, up from $504k to $2.98mm, while cutting total Dev/R&D by $12.3mm or 78% ($15.6mm to $3.3mm-before credits) GN Iwinshortslose2 0 4/22/2018 5:31:52 PM
24262 Re: Facts: In 5 year period from 2013 thru 2017 re-engineered Development/R&D spending for Manocept/Macrophage up by a nearly 500% increase, up from $504k to $2.98mm, while cutting total Dev/R&D by $12.3mm or 78% ($15.6mm to $3.3mm-before credits) GN dwdinvesting 1 4/22/2018 5:23:15 PM
Previous 2500 Messages Top of Message List
Go to Msg #  


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2016 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...